Related Experiment Video
Updated: Jan 10, 2026
Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies
Published on: January 31, 2025
Identification of Protein Markers for Chronic Ischemic Heart Disease Through Integrated Analysis of the Human Plasma
Chunyang Ren1,2, Gan Qiao1,2, Jianping Wu1
1Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou 646000, China.
Insights
This study identified 28 protein markers for chronic ischemic heart disease (CIHD), including three priority therapeutic targets: CXCL12, PLAU, and CD14. These findings offer new insights into CIHD treatment strategies.
Area of Science:
- Cardiovascular Research
- Proteomics
- Genetics
Background:
- Chronic ischemic heart disease (CIHD) results from persistent myocardial ischemia due to reduced coronary blood flow.
- Current treatments for CIHD are limited, highlighting the need for novel therapeutic targets.
- Proteomics offers a valuable approach for identifying potential therapeutic targets in CIHD.
Purpose of the Study:
- To identify novel protein biomarkers associated with CIHD using a Mendelian randomization approach.
- To investigate the pathways and druggability of identified protein biomarkers for CIHD.
- To discover potential therapeutic targets for CIHD.
Main Methods:
- Bidirectional Mendelian randomization analysis integrating CIHD GWAS data with plasma proteomic data (4907 proteins).
- Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis.
- Database searches (NGDC, DSIGDB, ChEMBL) and clinical trial data for evidence and druggability assessment.
Main Results:
- Identified 28 protein markers for CIHD, including 16 risk-associated and 12 protective proteins.
- Confirmed five newly discovered protein markers associated with CIHD.
- Prioritized three therapeutic targets (CXCL12, PLAU, CD14) for further development.
Conclusions:
- This research identified novel biomarkers and pathways implicated in CIHD.
- The study provides valuable insights into target identification and druggability for CIHD.
- CXCL12, PLAU, and CD14 represent promising therapeutic targets for chronic ischemic heart disease.
Background:
Chronic ischemic heart disease (CIHD) is characterized by persistent myocardial ischemic due to long-term reduced coronary blood flow. In the past, we mainly relied on surgical intervention or drug therapy to alleviate symptoms, but effective targeted treatments were scarce. Proteomics serves as a key tool to identify novel therapeutic targets.
Methods:
This study performed a bidirectional Mendelian randomization (MR) analysis by integrating genome-wide association study (GWAS) data on CIHD (10,894,596 single-nucleotide polymorphisms) with plasma proteomic data encompassing 4907 proteins. We conducted Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis to identify pathways linked to candidate protein biomarkers, searched the National Genomics Data Center (NGDC) database for existing evidence of their association with CIHD, and evaluated druggability through multi-dimensional analysis integrating the DSIGDB, ChEMBL, and clinical trial databases.
Results:
After eliminating the reverse effect, ultimately identifying 28 protein markers, including 16 risk-associated and 12 protective proteins. We also investigated their roles in the pathways related to CIHD. Meanwhile, the search confirmed that five of them were newly discovered protein markers. Ultimately, through evaluation, three priority therapeutic targets (CXCL12, PLAU, CD14) were identified for development.
Conclusions:
This study identified some biomarkers related to CIHD and analyzed the possible pathways involved. It also provided some new insights into the identification of the target and druggability.
More Related Videos
08:51Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
Published on: September 20, 2024
07:54Dynamic Proteomic and miRNA Analysis of Polysomes from Isolated Mouse Heart After Langendorff Perfusion
Published on: August 29, 2018
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:11Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
01:33Proteomics
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term...